'Cures' resurrects orphan exclusivity; 'Dormant' protection dead?
This article was originally published in Scrip
Patient advocates lavished quick praise on lawmakers for including a measure in the latest version of the 21st Century Cures Act, unveiled on 13 May, which would extend by six months the exclusivity protection for marketed drugs that seek and gain new indications aimed at preventing, diagnosing or treating rare diseases or conditions.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.